Provided by Tiger Fintech (Singapore) Pte. Ltd.

CMS

13.990
+0.2401.75%
Volume:8.95M
Turnover:123.63M
Market Cap:34.14B
PE:19.19
High:14.040
Open:13.830
Low:13.550
Close:13.750
52wk High:15.630
52wk Low:6.523
Shares:2.44B
HK Float Shares:2.44B
Volume Ratio:1.34
T/O Rate:0.37%
Dividend:0.30
Dividend Rate:2.13%
EPS(LYR):0.729
ROE:9.91%
ROA:5.58%
PB:1.84
PE(LYR):19.19
PS:3.98

Loading ...

CMS (00867) Receives Clinical Trial Approval for Class 1 New Drug MG-K10 Humanized Monoclonal Antibody Injection for Chronic Obstructive Pulmonary Disease Indication

Stock News
·
Yesterday

China Medical System Holdings Ltd. Receives NMPA Approval to Begin Clinical Trials of MG-K10 Monoclonal Antibody Injection for COPD

Reuters
·
Yesterday

China Medical System Holdings Ltd - Announces Mg-K10 Drug Trial Approval by Nmpa

THOMSON REUTERS
·
Yesterday

China Medical System Unit Receives Regulatory Nod to Conduct Phase 3 Trial of Skin Drug

MT Newswires Live
·
Sep 29

Hong Kong Stock Early Insight | Eight Departments Issue Guidelines to Promote Non-Ferrous Metals Industry Stable Growth, Hong Kong to Build Global Fixed Income and Currency Products Hub

Stock News
·
Sep 29

China Medical System Holdings Receives NMPA Approval to Conduct Phase III Clinical Trials of Innovative MG-K10 Monoclonal Antibody for Chronic Spontaneous Urticaria in Mainland China

Reuters
·
Sep 28

CMS (00867): Class 1 New Drug MG-K10 Humanized Monoclonal Antibody Injection Receives Additional Phase III Clinical Trial Approval for Chronic Spontaneous Urticaria Indication

Stock News
·
Sep 28

China Medical System Holdings Limited Approval of Phase Iii Drug Clinical Trials for Chronic Spontaneous Urticaria Indication of Mg-K10

THOMSON REUTERS
·
Sep 28

China Medical System (867.HK; 8a8.SG) Positive Results From China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream With Ad Indication

THOMSON REUTERS
·
Sep 28

China Medical System Holdings Limited Approval of Drug Clinical Trials for Uterine Fibroids Indication of Innovative Drug CMS-D002

THOMSON REUTERS
·
Sep 26

CMS (00867): Innovative Drug Ruxolitinib Phosphate Cream Achieves Positive Results in Phase III Clinical Trial for Atopic Dermatitis in China

Stock News
·
Sep 26

CMS (00867): Innovative GnRH Receptor Antagonist CMS-D002 Receives Clinical Trial Approval for Uterine Fibroids Indication

Stock News
·
Sep 26

China Medical System Holdings Announces Positive Phase 3 Trial Results for Ruxolitinib Cream in Chinese Atopic Dermatitis Patients

Reuters
·
Sep 26

China Medical System Holdings Ltd. Receives NMPA Approval to Initiate Clinical Trials for Innovative GnRH Receptor Antagonist CMS-D002 in Uterine Fibroids

Reuters
·
Sep 26

China Medical System Holdings Ltd - Gets Nmpa Approval for CMS-D002 Trial

THOMSON REUTERS
·
Sep 26

China Medical System (867.HK; 8a8.SG) Signed Collaboration Agreements for Two Innovative Biologics Used for Passive Immunization Against Tetanus and Rabies

THOMSON REUTERS
·
Sep 23

CMS (00867; 8A8.SG) Reaches Cooperation Agreement for Two Innovative Biological Products: Vikontamab Injection for Tetanus Passive Immunization and Siravemab Injection for Rabies Passive Immunization

Stock News
·
Sep 23

BRIEF-China Medical System Entered Into Two Separate Exclusive Collaboration Agreements

Reuters
·
Sep 22

China Medical System Holdings Ltd. Announces Collaboration Agreements for Innovative Biologic Products

Reuters
·
Sep 22

China Medical System - Entered Into Two Seperate Exclusive Collaboration Agreements With Chongqing Genrix Biopharmaceutical

THOMSON REUTERS
·
Sep 22